Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 8/20 | 0.46 |
| ▸ | TLR4 | O00206 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872515 | 0.84 | HPGD (0.53) | KMT2ACYP3A4CYP2C9CYP2C19PTGES2 | |
| SCHEMBL856209 | 0.84 | CYP3A4 (0.57) | KMT2ACYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL6196899 | 0.82 | KMT2A (0.64) | KMT2APTGES2TLR4 | |
| SCHEMBL31388990 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL16492686 | 0.78 | KMT2A (0.55) | KMT2ATLR4 | |
| SCHEMBL1462080 | 0.76 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19KITBRAF | |
| SCHEMBL1442576 | 0.76 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19KITBRAF | |
| SCHEMBL22315270 | 0.76 | KMT2A (0.59) | KMT2APTGES2 | |
| SCHEMBL13961979 | 0.75 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2C19KITBRAF | |
| SCHEMBL20290537 | 0.74 | KMT2A (0.51) | KMT2APTGES2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | KMT2A 714/4885CYP3A4 3611/4885CYP2C9 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.